Provided by Tiger Trade Technology Pte. Ltd.

SIHUAN PHARM

0.875
-0.030-3.31%
Volume:30.37M
Turnover:26.59M
Market Cap:7.99B
PE:38.06
High:0.900
Open:0.900
Low:0.865
Close:0.905
52wk High:1.896
52wk Low:0.810
Shares:9.13B
HK Float Shares:9.13B
Volume Ratio:1.18
T/O Rate:0.33%
Dividend:0.02
Dividend Rate:2.60%
EPS(LYR):0.023
ROE:3.13%
ROA:2.69%
PB:1.17
PE(LYR):38.06
PS:2.61

Loading ...

Hong Kong Stock Movers | Sihuan Pharma Surges Over 6% on Strong H1 Profit Forecast and Expanding Aesthetic Medicine Business

Stock News
·
Aug 20

Sihuan Pharmaceutical Sets 26 Aug 2026 Board Meeting to Approve H1 2026 Results and Consider Interim Dividend

Bulletin Express
·
Aug 14

Xuanzhu Biopharmaceutical Sets Board Meeting to Review Interim Results

Reuters
·
Aug 13

Sihuan Pharmaceutical Holdings Group (SEHK:460) Looks Pricey On 2026 Earnings Guidance

Simply Wall St.
·
Jul 28

Sihuan Pharmaceutical Hits Nearly 9-week High on Robust Earnings Estimates

Reuters
·
Jul 27

Hong Kong Stock Market Moves: SIHUAN PHARM Surges Over 4% as First-Half Net Profit Expected to Jump at Least 217.2% Year-on-Year, with Medical Aesthetics Business Maintaining Steady Growth

Stock News
·
Jul 27

Sihuan Pharmaceutical Expects H1 Profit to Soar At Least 217%

MT Newswires Live
·
Jul 27

Sihuan Pharmaceutical Shifts Bermuda Registered Office and Registrar to New Hamilton Address

Bulletin Express
·
Jul 27

SIHUAN PHARM Predicts First-Half Net Profit Surge of Over 217.2%

Stock News
·
Jul 27

Sihuan Pharma - Sees Hy Net Profit of not Less than Rmb210 Mln

THOMSON REUTERS
·
Jul 27

Sihuan Pharma - Expects H1 Revenue of at Least Rmb1,140 Mln and Net Profit of at Least Rmb210 Mln

THOMSON REUTERS
·
Jul 27

Xuanzhu Biopharma Ordered to Pay RMB 9.33 Million in Cietac Arbitration Award

Reuters
·
Jul 19

SIHUAN PHARM Shares Surge Over 12% in Early Trading Following Publication of Key Clinical Study

Stock News
·
Jul 14

Sihuan Pharma Says NMPA Accepts NDA for Anaprazole Sodium for Reflux Esophagitis

Reuters
·
Jul 06

Sihuan Pharmaceutical Holdings Group (SEHK:460) Following Phase III Trial Progress Is The Stock Too Pricey

Simply Wall St.
·
Jul 03

Sihuan Pharmaceutical Unit's Reflux Esophagitis Drug Application Accepted in China

MT Newswires Live
·
Jun 30

NMPA Accepts Sihuan Pharmaceutical Subsidiary Xuanzhu Biopharm’s NDA for Anaprazole Sodium in Reflux Esophagitis

Bulletin Express
·
Jun 30

Xuanzhu Biopharma Says NMPA Accepts NDA for Anaprazole Sodium in Reflux Esophagitis

Reuters
·
Jun 30

Sihuan Pharmaceutical AGM Clears All Resolutions; Final Dividend Set at HK1.09 Cents per Share

Bulletin Express
·
Jun 26

Sihuan Pharmaceutical Shareholders Approve RMB 0.96 Cent Final Dividend for 2025

Reuters
·
Jun 26